FDA Grants Priority Review To Lovenox® (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) For Additional Type Of Heart Attack

... Sanofi-aventis announced today the Food and Drug Administration (FDA) has accepted for review a supplemental new drug application (sNDA) for the anticoagulant Lovenox® (enoxaparin sodium injection) for the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI), a type of acute heart attack. [click link for full article] ...